BMRA Biomerica
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other Foreign. The company was founded in September 1971 and is headquartered in Irvine, CA.
Company profile
Ticker
BMRA
Exchange
Website
CEO
Zackary S. Irani
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NMS PHARMACEUTICALS INC, NUCLEAR MEDICAL SYSTEMS INC, NUCLEAR INSTRUMENTS INC
SEC CIK
Corporate docs
IRS number
952645573
BMRA stock data
()
Investment data
Securities sold
Number of investors
Calendar
14 Apr 21
17 Apr 21
31 May 21
Financial summary
Quarter (USD) |
Feb 21 | Nov 20 | Aug 20 | May 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
May 20 | May 19 | May 18 | May 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from Biomerica earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 5.27M | 5.27M | 5.27M | 5.27M | 5.27M | 5.27M |
| Cash burn (monthly) | 137.07K | (positive/no burn) | 626.7K | 458.68K | 454.62K | 644.89K |
| Cash used (since last report) | 228.26K | n/a | 1.04M | 763.81K | 757.04K | 1.07M |
| Cash remaining | 5.04M | n/a | 4.23M | 4.51M | 4.52M | 4.2M |
| Runway (months of cash) | 36.8 | n/a | 6.7 | 9.8 | 9.9 | 6.5 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 10 Dec 20 | Zackary S. Irani | NQSO Common Stock | Grant | Aquire A | No | No | 6.36 | 78,616 | 500K | 633,616 |
| 10 Dec 20 | Steven Sloan | NQSO Common Stock | Grant | Aquire A | No | No | 6.36 | 25,000 | 159K | 75,000 |
| 10 Dec 20 | Barbieri Allen | NQSO Common Stock | Grant | Aquire A | No | No | 6.36 | 30,000 | 190.8K | 220,000 |
| 10 Dec 20 | Sirgo Mark A | NQSO Common Stock | Grant | Aquire A | No | No | 6.36 | 20,000 | 127.2K | 145,000 |
| 10 Dec 20 | Catherine Coste | NQSO Common Stock | Grant | Aquire A | No | No | 6.36 | 20,000 | 127.2K | 45,000 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
39.0% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 31 |
| Opened positions | 8 |
| Closed positions | 3 |
| Increased positions | 11 |
| Reduced positions | 7 |
13F shares |
Current |
|---|---|
| Total value | 29.8M |
| Total shares | 4.58M |
| Total puts | 55.1K |
| Total calls | 0 |
| Total put/call ratio | Infinity |
Largest owners |
Shares | Value |
|---|---|---|
| WELLINGTON TRUST Co N A | 866K | $4.31M |
| Wellington Management | 866K | $4.31M |
| Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio | 723.2K | $3.6M |
| Vanguard | 567.7K | $2.83M |
| Granahan Investment Management | 510.92K | $2.54M |
| Russell Investments | 393.4K | $1.96M |
| BLK Blackrock | 210.03K | $1.05M |
| Millrace Asset | 72.08K | $359K |
| Heritage Investors Management | 69.35K | $345K |
| Geode Capital Management | 64.28K | $320K |
Financial report summary
?Management Discussion
- Our consolidated net sales were $6,692,711 for fiscal 2020 compared to $5,200,682 for fiscal 2019. This represents an increase of $1,492,029, or 28.7%. This increase in annual sales is primarily attributable to sales of COVID-19 tests during the last quarter of the fiscal year, which offset decreases in other product lines that were negatively impacted by the COVID-19 pandemic and related national and international mandates affecting consumers. Our consolidated net sales were $2,725,000 for the fiscal fourth quarter 2020, compared to $1,165,860 for fiscal fourth quarter of 2019.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
American, called, choose, compliance, Concurrently, default, downturn, EZ, failed, fell, hundred, internationally, launch, launched, longer, Moderna, moving, NASDAQ, ownership, percent, Pfizer, protein, readily, RNA, shifted, spike, typically, website
Removed:
ASU, finger, higher, institution, prick, promising, similar, standard
Financial reports
10-Q
2021 Q3
Quarterly report
14 Apr 21
10-Q
2021 Q2
Quarterly report
14 Jan 21
10-Q
2021 Q1
Quarterly report
15 Oct 20
10-K
2020 FY
Annual report
31 Aug 20
10-Q
2020 Q3
Quarterly report
14 Apr 20
10-Q
2020 Q2
Quarterly report
14 Jan 20
10-Q
2020 Q1
Quarterly report
15 Oct 19
10-K
2019 FY
Annual report
29 Aug 19
10-Q
2019 Q3
Quarterly report
15 Apr 19
10-Q
2019 Q2
Quarterly report
14 Jan 19
Current reports
8-K
Other Events
22 Jan 21
8-K
Biomerica’S Fast 15-Minute Simple to use COVID-19 Antigen RAPID test receives CE Mark
13 Jan 21
8-K
Submission of Matters to a Vote of Security Holders
11 Dec 20
8-K
Departure of Directors or Certain Officers
11 Dec 20
8-K
Regulation FD Disclosure
1 Sep 20
8-K
Departure of Directors or Certain Officers
1 Sep 20
8-K
Regulation FD Disclosure
28 Jun 20
8-K
Regulation FD Disclosure
16 Jun 20
8-K
Regulation FD Disclosure
1 Jun 20
8-K
Regulation FD Disclosure
8 May 20
Registration and prospectus
424B5
Prospectus supplement for primary offering
22 Jan 21
S-3/A
Shelf registration (amended)
11 Sep 20
S-3
Shelf registration
21 Jul 20
424B5
Prospectus supplement for primary offering
20 Mar 20
D
$2M in equity, sold $2M, 1 investor
27 Feb 20
S-8
Registration of securities for employees
10 May 18
424B5
Prospectus supplement for primary offering
3 Dec 17
S-3
Shelf registration
29 Jun 17
8-A12B
Registration of securities on exchange
22 Aug 16
S-8
Registration of securities for employees
21 May 15
Proxies
DEF 14A
Definitive proxy
25 Sep 20
DEF 14A
Definitive proxy
24 Sep 19
DEF 14A
Definitive proxy
27 Sep 18
DEF 14A
Definitive proxy
27 Sep 17
DEF 14A
Definitive proxy
27 Sep 16
DEF 14A
Definitive proxy
27 Sep 15
DEF 14A
Definitive proxy
28 Sep 14
DEF 14A
Definitive proxy
29 Sep 13
DEF 14A
Definitive proxy
27 Sep 12
DEF 14A
Definitive proxy
27 Sep 11
Other
EFFECT
Notice of effectiveness
1 Oct 20
CORRESP
Correspondence with SEC
27 Sep 20
CORRESP
Correspondence with SEC
10 Sep 20
CORRESP
Correspondence with SEC
8 Sep 20
UPLOAD
Letter from SEC
27 Jul 20
EFFECT
Notice of effectiveness
19 Jul 17
CORRESP
Correspondence with SEC
17 Jul 17
UPLOAD
Letter from SEC
5 Jul 17
UPLOAD
Letter from SEC
16 Mar 09
CORRESP
Correspondence with SEC
15 Mar 09
Ownership
SC 13G
BIOMERICA / WELLINGTON MANAGEMENT ownership change
3 Feb 21
SC 13G/A
BIOMERICA / Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio ownership change
3 Feb 21
SC 13G
BIOMERICA / WELLINGTON TRUST Co N A ownership change
3 Feb 21
SC 13G/A
BIOMERICA / Intelligent Fanatics Capital Management ownership change
20 Jan 21
4
BIOMERICA / FRANCIS CANO ownership change
11 Dec 20
4
BIOMERICA / Jane Emerson ownership change
11 Dec 20
4
BIOMERICA / Catherine Coste ownership change
11 Dec 20
4
BIOMERICA / Mark A Sirgo ownership change
11 Dec 20
4
BIOMERICA / ALLEN BARBIERI ownership change
11 Dec 20
4
BIOMERICA / Steven Sloan ownership change
11 Dec 20
Patents
GRANT
Utility
IBS sensitivity testing
28 Sep 20
Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value.
APP
Utility
Compositions, Devices, and Methods of Attention Deficit Disorder/attention Deficit Hyperactivity Disorder (Add/adhd) Sensitivity Testing
1 Jan 20
Contemplated test kits, diagnostic apparatus and methods using same for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value.